CONTENTS

Chapter 1  General introduction  9

Chapter 2  Study protocol of the RAND study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia

BMC Cancer 2014; 14:247

Chapter 3  Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of patients with chronic myeloid leukemia treated with nilotinib

Submitted

Chapter 4  Patient satisfaction with information on oral anticancer agent use

Cancer Medicine 2018; 7(1):219-228

Chapter 5  Satisfaction with information on nilotinib treatment in chronic myeloid leukemia patients

Acta Oncologica 2019; 58(6):891-896

Chapter 6  Needs for information and reasons for (non)adherence in chronic myeloid leukemia: Be aware of social activities disturbing daily routines

European Journal of Haematology 2018; 101:643-653

Chapter 7  Food-effect study of nilotinib in chronic myeloid leukemia (NiFo study): enabling dose reduction and relief of treatment burden

Submitted
Chapter 8  Dried blood spot sampling of nilotinib in patients with chronic myeloid leukemia: a comparison with venous blood sampling
Journal of Pharmacy and Pharmacology 2017; 69(10):1265-1274

Chapter 9  Feasibility of and patients’ perspective on nilotinib dried blood spot self-sampling
European Journal of Clinical Pharmacology 2019; 75(6):825-829

Chapter 10  Summary, recommendations, and perspectives

Nederlandse samenvatting 213
Dankwoord 225
Curriculum Vitae 229
List of publications 231